Searched for
JB PHARMA EARNINGS
Market Trading Guide: Allied Blenders among 2 stock recommendations for FridayDomestic markets recovered modestly on easing oil prices and selective buying in banking and pharma stocks. Analysts have recommended Allie...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Buy, Sell or Hold: Citi keeps a buy on Torrent Pharmaceuticals; Morgan Stanley maintains overweight on Reliance IndustriesBrokerages remain positive on select stocks, with Citigroup maintaining a buy rating on Torrent Pharmaceuticals and Morgan Stanley keeping ...
- Torrent Pharma shares in focus after CCI clears Rs 19,500 crore acquisition of JB ChemicalsTorrent Pharmaceuticals shares are expected to see activity. The Competition Commission of India has approved Torrent Pharma's plan to acqu...
- JB Chemicals shares fall over 6% as Torrent makes open offer at 9% discountJB Chemicals & Pharmaceuticals shares declined after KKR announced the sale of its stake to Torrent Pharma, valuing JB Pharma at Rs 25,689 ...
- JB Pharma Q1 Results: Net profit jumps 25% YoY to Rs 177 croreThe drug maker had reported a net profit of Rs 142 crore in the year-ago period.Revenue for the quarter rose 12% YoY to Rs 1004 crore
- JB Pharma expects India business to grow above market growth rate in FY25: CEO Nikhil ChopraJB Pharma, led by CEO Nikhil Chopra, forecasts 12-14% revenue growth and aims to increase Ebitda margins by 27-28% in FY25. The growth is d...
- JB Pharma Q4 Results: Net profit jumps 43% YoY to Rs 126 croreThe Mumbai-based company reported operating earnings before interest, taxes, depreciation and amortisation (EBITDA) at Rs 210 crore, up fro...
- Hot Stocks: Brokerages view on Trent, Nazara Technologies, Nestle and JB PharmaCitigroup maintained a buy rating on Nestle India post Q3 results with a target price of Rs 2900. The company reported steady revenue growt...
- JB Pharma Q3 Results: Net profit jumps 26% to Rs 134 croreThe drug maker had reported a net profit of Rs 106 crore in the year-ago period. Revenue for the quarter rose 7% YoY to Rs 845 crore The Mu...
- JB Pharma Q2 Results: Net profit jumps 35% YoY to Rs 151 croreRevenue for the quarter rose 9% YoY to Rs 882 crore. The Mumbai-based company reported operating earnings before interest, taxes, depreciat...
- JB Pharma Q1 Results: Net profit surges 35% YoY to Rs 142 croreDomestic business revenue grew 17% YoY to Rs 489 crores in Q1FY24, despite sales for the acute business being impacted due to the delayed m...
- JB Pharma Q4 Results: Net profit rises 4% to Rs 88 croreOperating cash flow improved in FY23 to Rs 626 crores as compared to Rs 170 crores in FY22, strongly aided by the higher proportion of Indi...
- JB Pharma Q3 Results: Net profit rises 26% to Rs 106 croreThe earnings before interest, tax, depreciation and ammortisation (EBITDA) rose 28% YoY to Rs 193 crore. The EBTIDA margin dropped 120 basi...
- JB Pharma profit rises 13% to Rs 111 crore in Q2FY23Revenues rose 36% YoY to Rs 809 crore in Q2FY23, compared to Rs 593 crore in Q2FY22.Earnings before interest, depreciation and taxes (EBITD...
- JB Pharma net profit down 12% to Rs 105 croreThe company reported net profit of Rs 119 crore during corresponding period of the previous year.The company attributed the drop in net pro...
- JB Chemicals stock has more steam left in itKKR, which assumed control beginning this month, has made swift changes to the company's board of directors and senior management.
- High pressure on pharma margins; buy JB Chemicals: SharekhanLupin and Glenmark as clear winners with a likely upside from Para IV/niche opportunities, strong domestic franchise, low vulnerability to ...
Load More
